Alembic Pharmaceuticals Limited has fixed Wednesday, July 29, 2026, as the record date to determine shareholder eligibility for the dividend payment for the financial year 2025-26, subject to approval at the upcoming Annual General Meeting (AGM). The 16th AGM is scheduled for Wednesday, August 5, 2026, at 4:00 P.M. IST via video conferencing. The meeting will be conducted in compliance with the Companies Act, 2013, and the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board emphasized that dividend payments will be made exclusively through electronic mode. Shareholders holding physical share certificates must ensure their folios are updated with the Registrar and Transfer Agent, MUFG Intime India Pvt. Ltd., by Friday, July 24, 2026. Required updates include the Permanent Account Number (PAN), contact details, mobile number, bank account details, and specimen signature. Failure to update these details may result in a delay or inability to receive the dividend.

The Annual Report and Notice of AGM will be sent only to members whose email addresses are registered with the company or depositories. These documents will also be available on the company's website and the websites of BSE Limited and National Stock Exchange of India Limited. The notice will additionally be accessible on the National Securities Depository Limited website.

In accordance with the Income Tax Act, 2025, the company will deduct tax at source (TDS) on dividends at prescribed rates. The applicable TDS rate depends on the shareholder's residential status and the documentation submitted. Shareholders are advised to update their PAN and submit relevant forms, such as Form 121 / 41 or Tax Residency Certificates, to the Registrar to avoid higher tax deductions.

Alembic Pharmaceuticals has executed a Shareholders' Agreement to invest in a newly incorporated Canadian Corporation, securing a 45% equity stake to establish a platform for the development and commercialization of pharmaceutical products in the Canadian market. The agreement was signed on June 6, 2026, with Difgen Holdings LLC and Mr. Sukhad Juneja to invest in the shares of 17989377 Canada Inc. Post-investment, the Canadian Corporation will become an associate of Alembic Pharmaceuticals.

Joint Venture Structure

The joint venture involves Alembic Pharmaceuticals and Difgen Holdings LLC each holding a 45% shareholding, while others will hold the remaining 10%. The board of directors of the Canadian Corporation will comprise nominee directors of the shareholders along with an independent director. The agreement provides for customary shareholder rights, including participation in key decision matters.

Shareholding Pattern

Regulatory Compliance

The disclosure was made to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirmed that the parties to the joint venture are not related to the promoter, promoter group, or group companies of Alembic Pharmaceuticals in any manner. Furthermore, the investment does not fall within the purview of a Related Party Transaction for the company. The document also confirmed that there is no potential conflict of interest arising out of this agreement, and the specific details regarding the issue price and class of shares were noted as not applicable in the regulatory filing. Manisha Saraf, Company Secretary of Alembic Pharmaceuticals, submitted the intimation to BSE Limited and the National Stock Exchange of India Ltd.